The present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding a bile salt hydrolase enzyme and/or a 7α-dehydroxylating enzyme. In another aspect, the recombinant bacterial cells further comprise a bacterial kill switch. The disclosure further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders associated with bile salts, such as cardiovascular disease, metabolic disease, liver disease (such as cirrhosis or nonalcoholic steatohepatitis (NASH), C. difficile infection, and cancer, using the pharmaceutical compositions of the disclosure.